SANA
NASDAQSana Biotechnology Inc.
Price$3.13+0.04 (+1.46%)
01:30 PM07:45 PM
News · 26 weeks49-73%
2026-01-182026-07-12
Mix2890d
- Other9(32%)
- Insider9(32%)
- SEC Filings8(29%)
- Analyst1(4%)
- Leadership1(4%)
Latest news
25 items- PRThe Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho TherapyIssued on behalf of Avaí Bio, Inc.As cell-based medicine moves from the lab toward the clinic across diabetes, transplant, and aging, Avaí Bio and partner Austrianova have banked the genetically modified cells that will manufacture their encapsulated alpha-Klotho productLAS VEGAS, July 8, 2026 /CNW/ -- USA News Group News Commentary - The most valuable real estate in medicine right now is a living cell. Across diabetes, organ transplant, and the fast-emerging field of longevity biology, developers are racing to turn engineered and donor-derived cells into durable, manufacturable therapies, and the companies that reach GMP-grade production first are the ones the market takes seriously. That i
- INSIDERDirector Bishop Hans Edgar was granted 6,297 shares, increasing direct ownership by 0.11% to 5,854,800 units (SEC Form 4)4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- PRSana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune platform (HIP) technology, into a patient with type 1 diabetes without any immunosuppression. The symposium will be held at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 taking place from September 28 - October 2, 2026 in Milan, Italy. Symposium Title:Stem cell-derived islets in clin
- INSIDERSEC Form 4 filed by Director Yang Patrick Y4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDERSEC Form 4 filed by Director Rosiello Robert L.4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDERSEC Form 4 filed by Director Seitz Michelle4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDERSEC Form 4 filed by Director Reicin Alise4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDERSEC Form 4 filed by Director Mulligan Richard4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDERSEC Form 4 filed by Director Bishop Hans Edgar4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDERSEC Form 4 filed by Director Bilenker Joshua H.4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- INSIDERSEC Form 4 filed by Director Nelsen Robert4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
- SECSana Biotechnology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
- PRAnti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain MomentumUSA News Group News CommentaryIssued on behalf of Avaí Bio, Inc.As the broader cell and gene therapy complex posts record quarterly revenue and advances toward accelerated approval pathways, a Nevada-based longevity joint venture has just cleared a manufacturing-stage gate on its α-Klotho anti-aging program.NEW YORK, May 28, 2026 /CNW/ -- Cell and gene therapy has crossed a meaningful inflection in 2026. Vertex Pharmaceuticals reported Q1 product revenue of $2.99 billion, with newer non-CF franchises CASGEVY and JOURNAVX contributing more than 25% of year-over-year growth. Alnylam Pharmaceuticals delivered its first-ever $1 billion product revenue quarter. Beam Therapeutics presented updated
- PRSana Biotechnology to Present at June 2026 Investor ConferencesSEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update. Sana will present at the Jefferies Global Healthcare Conference at 9:20 a.m. ET on Wednesday, June 3, 2026.Sana will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 4:00 p.m. ET on Tuesday, June 9, 2026. The webcasts will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of each presentation will be availab
- SECSEC Form SCHEDULE 13G filed by Sana Biotechnology Inc.SCHEDULE 13G - Sana Biotechnology, Inc. (0001770121) (Subject)
- SECSEC Form 8-K filed by Sana Biotechnology Inc.8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
- PRSana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) FacilitySEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21,607,878 shares of the company's common stock through its at-the-market ("ATM") facility established through TD Securities (USA) LLC for net proceeds of approximately $69 million. The investment, including participation based on interest received from RA Capital Management, combined with the previously announced unrelated $25 million investment from the Mayo Clinic, brings the total capital raised since the end of the first quarter of 2026 to approximately $94 million and exten
- PRSana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPsSEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of preclinical data demonstrating that a surrogate SG293, an in vivo CAR T cell therapy, achieved cell-specific delivery, robust and dose-dependent CAR T cell generation, and deep B cell depletion in non-human primates (NHPs) without the use of lymphodepleting chemotherapy. SG293 is a CD8-targeted fusosome that delivers the genetic material to make CD19-directed CAR T cells. The data were reported in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting.
- SECSEC Form S-8 filed by Sana Biotechnology Inc.S-8 - Sana Biotechnology, Inc. (0001770121) (Filer)
- SECSEC Form 10-Q filed by Sana Biotechnology Inc.10-Q - Sana Biotechnology, Inc. (0001770121) (Filer)
- SECSana Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
- PRSana Biotechnology Reports First Quarter 2026 Financial Results and Business UpdatesAnnounced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later this year, including manufacturing readiness, non-clinical testing, and clinical trial preparation Announced positive clinical results at 14 months from ongoing clinical trial transplanting UP421 without any immunosuppression into a patient with type 1 diabetes, showing ongoing survival and function Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma later this year, including manufacturing readiness, non-clinical testing, and clinical trial preparation Will prese
- ANALYSTRodman & Renshaw initiated coverage on Sana Biotechnology with a new price targetRodman & Renshaw initiated coverage of Sana Biotechnology with a rating of Buy and set a new price target of $16.00
- PRSana Biotechnology to Present at the BofA Securities 2026 Healthcare ConferenceSEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2026 Healthcare Conference at 2:20 p.m. PT on Tuesday, May 12, 2026. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of the presentation will be available at the same location for 30 days following the conference. About Sana BiotechnologySana Biotechnology, Inc. is focu
- PRSana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual MeetingSEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting preclinical data from SG293, its CD19-directed in vivo CAR T product candidate, has been accepted for oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting taking place May 11-15, 2026 in Boston, MA. Oral Presentation: Title:Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293Summary:SG293 represents a differentiated approach for enabling potent and precise in vivo CAR T therapy for both oncology and autoimmune
SANA FAQ
7 questionsWhat does Sana Biotechnology Inc. do?
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for...Where does SANA stock trade?
Sana Biotechnology Inc. (SANA) is listed on NASDAQ.What sector and industry is SANA in?
Sana Biotechnology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Sana Biotechnology Inc. go public?
Sana Biotechnology Inc. (SANA) completed its IPO in 2021.What are analysts saying about SANA?
Sana Biotechnology Inc. has had 8 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $1600.00 price target on 2026-05-11. Recent price targets range from $500.00 to $1600.00.What companies are similar to SANA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare SANA side-by-side with any of them on Quantisnow.How can I track SANA on Quantisnow?
Quantisnow aggregates Sana Biotechnology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SANA to receive live email and push alerts on every new disclosure.